Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris
- 10 September 2009
- journal article
- research article
- Published by Springer Nature in Archiv für die gesamte Virusforschung
- Vol. 154 (10) , 1609-1617
- https://doi.org/10.1007/s00705-009-0484-8
Abstract
Human papillomaviruses (HPVs) are responsible for the most common human sexually transmitted viral infections. Infection with high-risk HPVs, particularly HPV16, is associated with the development of cervical cancer. The papillomavirus L1 major capsid protein, the basis of the currently marketed vaccines, self-assembles into virus-like particles (VLPs). Here, we describe the expression, purification and characterization of recombinant HPV16 L1 produced by a methylotrophic yeast. A codon-optimized HPV16 L1 gene was cloned into a non-integrative expression vector under the regulation of a methanol-inducible promoter and used to transform competent Pichia pastoris cells. Purification of L1 protein from yeast extracts was performed using heparin–sepharose chromatography, followed by a disassembly/reassembly step. VLPs could be assembled from the purified L1 protein, as demonstrated by electron microscopy. The display of conformational epitopes on the VLPs surface was confirmed by hemagglutination and hemagglutination inhibition assays and by immuno-electron microscopy. This study has implications for the development of an alternative platform for the production of a papillomavirus vaccine that could be provided by public health programs, especially in resource-poor areas, where there is a great demand for low-cost vaccines.Keywords
This publication has 59 references indexed in Scilit:
- An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial resultsVaccine, 2008
- A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody ResponseJournal of Virology, 2008
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- A human papillomavirus type 16 vaccine by oral delivery of L1 proteinVirus Research, 2005
- The production of human papillomavirus type 16 L1 vaccine product from Escherichia coli inclusion bodiesBioprocess and Biosystems Engineering, 2002
- Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1Journal of Molecular Biology, 2001
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cellsFEMS Microbiology Letters, 1994
- Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.Journal of Clinical Pathology, 1990
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970